Update on the assessment of children with juvenile idiopathic inflammatory myopathy

Current Rheumatology Reports

Volumn 12, Issue 3, 2010, Pages 204-212

  Huber, Adam M ^a  

^a IWK HEALTH CENTRE   (Canada)

Author keywords

Assessment; JDM; JIIM; Juvenile dermatomyositis; Juvenile idiopathic inflammatory myopathy; Measurement

Indexed keywords

CHILD; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE EXACERBATION; ENDURANCE; HUMAN; JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHY; LABORATORY TEST; MEDICAL ASSESSMENT; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE STRENGTH; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REVIEW; SCORING SYSTEM; SKIN DISEASE; SKIN MANIFESTATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DATABASES, BIBLIOGRAPHIC; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MUSCLE STRENGTH; MUSCLE, SKELETAL; MYOSITIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN; SKIN DISEASES;

EID: 77953478025     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0103-4     Document Type: Review

References (51)

1. Mendez EP, Lipton R, Ramsey-Goldman R, et al.; NIAMS Juvenile DM Registry Physician Referral Group: US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003, 49:300-305.
2. Medical Research Council: Aids to the Investigation of Peripheral Nerve Injuries. Memorandum No. 7, edn 2. London: Her Majesty's Stationery Office; 1943.
3. Kendall FP, McCreary EK, Provance PG: Muscles: Testing and Function, edn 4. Baltimore, MD: Williams & Wilkins; 1993.
4. Jain M, Smith M, Cintas H, et al.: Intra-rater and inter-rater reliability of the 10-point manual muscle test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr 2006, 26:5-17.
5. Rider LG, Koziol D, Giannini EH, et al.: Validation of manual muscle testing and a subset or eight muscles (MMT8) for adult and juvenile idiopathic inflammatory myopathy. Arthritis Care Res 2010, 62(4): 465-472. This important study documents that the MMT8 has measurement characteristics that are similar to the full 26-muscle version.
6. Singh G, Athreya BH, Fries JF, Goldsmith DP: Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994, 37:1761-1769.
7. Feldman BM, Ayling-Campos A, Luy L, et al.: Measuring disability in juvenile dermatomyositis: validity of the Childhood Health Assessment Questionnaire. JRheumatol 1995, 22:326-331.
8. Huber AM, Hicks JE, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic inflammatory myopathies. J Rheumatol 2001, 28:1106-1111.
9. Lovell DJ, Lindsley CB, Rennebohm RM, et al.: Development of disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999, 42:2213-2219.
10. Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale (CMAS) for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004, 50:1595-1603.
11. Rennebohm RM, Jones K, Huber AM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale (CMAS). Arthritis Rheum 2004, 51:365-370.
12. Ruperto N, Ravelli A, Murray KJ, et al.; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003, 42:1452-1459.
13. Miller FW, Rider LG, Chung YL, et al.; International Myositis Outcome Assessment Collaborative Study Group: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2001, 40:1262-1273.
14. Hundley JL, Carroll CL, Lang W, et al.: Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006, 54:217-220.
15. Bode RK, Klein-Gitelman MS, Miller ML, et al.: Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Care Res 2003, 49:7-15.
16. Ruperto N, Ravelli A, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): The provisional Pediatric Rheumatology International Trials Organization/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008, 59:4-13. This study provides valuable validation of several measures used in the assessment of children with myositis, based on the PRINTO core set measures.
17. Isenberg D, Allen E, Farewell V, et al.; International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43:49-54.
18. Huber AM, Dugan EM, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: The Cutaneous Assessment Tool (CAT): development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007, 46:1606-1611.
19. Huber AM, Dugan EM, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Preliminary validation and clinical meaning of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis. Arthritis Rheum 2008, 59:214-221. This article provides validation for the only comprehensive skin assessment tool that is currently available.
20. Huber AM, Lachenbruch PA, Dugan EM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Alternative scoring of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis: results using an abbreviated format. Arthritis Rheum 2008, 59:352-356.
21. Carroll CL, Lang W, Snively B, et al.: Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008, 158:345-350.
22. Klein RQ, Bangert CA, Costner M, et al.: Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008, 159:887-894.
23. Yassaee M, Fiorentino D, Okawa J, et al.: Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. Br J Dermatol 2009 Oct 26 (Epub ahead of print).
24. Rider LG, Feldman BM, Perez MD, et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent and patient global assessments. Arthritis Rheum 1997, 40:1976-1983.
25. Rider LG, Lachenbruch PA, Monroe JB, et al.; IMACS Group: Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009, 60:3425-3435. This work validates the first (and currently only) damage assessment for children with myositis. It also documents and compares the extent of damage seen in both pediatric and adult myositis populations.
26. Landgraf J, Abetz L, Ware J: The CHQ User's Manual. Boston, MA: The Health Institute; 1996.
27. Apaz MT, Saad-Magalhães C, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation: Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009, 61:509-517. This is the only project to date to specifically study and validate a measure of health-related quality of life in a cohort of children with myositis.
28. Oddis CV, Rider LG, Reed AM, et al.; International Myositis Assessment and Clinical Studies Group: International consensus guidelines for the trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005, 52:2607-2615.
29. Rider LG, Giannini EH, Brunner HI, et al.; International Myositis Assessment and Clinical Studies Group: International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004, 50:2281-2290.
30. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
31. Rider LG, Schiffenbauer AS, Zito M, et al.; Juvenile Dermatomyositis Disease Activity Collaboration Study Group: Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 2002, 48:1681-1688.
32. O'Connor KA, Abbott KA, Sabin B, et al.: MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006, 120:319-325.
33. Bakay M, Wang Z, Melcon G, et al.: Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain 2006, 129:996-1013.
34. *0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002, 168: 4154-4163.
35. Fall N, Bove KE, Stringer K, et al.: Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis. Arthritis Rheum 2005, 52:3175-3180.
36. Baechler EC, Bauer JW, Slattery CA, et al.: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13:59-68.
37. Feldman BM, Rider LG, Reed AM, Pachman LM: Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371:2201-2212. This is an outstanding review of the current state of knowledge about the pathogenesis of juvenile myositis, written by four leaders in the field.
38. Bilgic H, Ytterberg SR, Amin S, et al.: Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009, 60:3436-3446. This study documents the association between type I interferon-regulated genes and chemokines with disease activity and provides significant optimism that laboratory-based assessments of disease activity may be approaching development.
39. Chung YL, Rider LG, Bell JD, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2005, 53:565-570.
40. Eisenstein DM, O'Gorman MR, Pachman LM: Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J Rheumatol 1997, 24:1830-1832.
41. O'Gorman MR, Bianchi L, Zaas D, et al.: Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis. Clin Diagn Lab Immunol 2000, 7:693-697.
42. McCann LJ, Juggins AD, Maillard SM, et al.; Juvenile Dermatomyositis Research Group: The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) - clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006, 45:1255-1260.
43. Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for Juvenile Dermatomyositis, Paediatric Rheumatology European Society (PReS): An international consensus survey on the diagnostic criteria for juvenile dermatomyositis. Rheumatology (Oxford) 2006, 45:990-993.
44. Wedderburn LR, Varsani H, Li CK, et al.: International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007, 57:1192-1201. This work describes an attempt to standardize and validate the assessment of muscle biopsy specimens in juvenile myositis.
45. Miles L, Bove KE, Lovell D, et al.: Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 2007, 57:1183-1191.
46. Gardner Medwin JM, Irwin G, Johnson K: MRI in juvenile idiopathic arthritis and juvenile dermatomyositis. Ann N Y Acad Sci 2009, 1154:52-83. This is an excellent review of the use of MRI in the assessment of children with myositis.
47. Maillard SM, Jones R, Owens C, et al.: Quantitative assessment of MRI T2 relaxation time in thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004, 43:603-608.
48. Tzaribachev N, Well C, Schedel J, Horger M: Whole-body MRI: a helpful diagnostic tool for juvenile dermatomyositis case report and review of the literature. Rheumatol Int 2009, 29:1511-1514.
49. Summers RM, Brune AM, Choyke PL, et al.: Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery imaging. Radiology 1998, 209:191-196.
50. Punaro L, Stichweh D, Powell M, et al.: Aspiration: hidden risk for patients with juvenile dermatomyositis [abstract]. Clin Exp Rheumatol 2004, 22(Suppl): S104.
51. McCann LJ, Garay SM, Ryan MM, et al.: Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 2007, 46:1363-1366.